Pneumonia is a life-threatening disease and at present, a large population of humans is affected by pneumonia worldwide. It is a serious issue causing complications of acquired immune deficiency syndrome infection. Most people are affected in low-and middle-income countries. Until now
pneumonia is mainly diagnosed by smear microscopy and is not easily available in the area of low-income settings. This research was conducted with a sensing strategy on interdigitated microelectrode (IDME) to identify the lower level of the target, ‘procalcitonin’. In addition,
procalcitonin can distinguish the community-acquired viral pathogens, which helps to provide a suitable treatment. IDME was physically modified by a silver nanoparticle, and an anti-procalcitonin antibody was attached to a silver nanoparticle with amine and aldehyde linkers. On this IDME,
procalcitonin was quantified in a dose-dependent manner (10–320 ng/mL) and calculated the detection limit to 10 ng/mL on a linear coefficient regression analysis [y = 2.2821×−2.6871; R2 = 0.9904]. Specific performances with control proteins that did
not increase the current were revealed the specific identification of procalcitonin. This experiment created a sensing strategy to identify procalcitonin as a suitable biomarker.